Summary
Despite advances in our understanding of the mechanisms underlying the progression of chronic kidney disease and the development of fibrosis, only limited efficacious therapies exist. The calcium binding protein S100A8/A9 is a damage‐associated molecular pattern which can activate Toll‐like receptor (TLR)‐4 or receptor for advanced glycation end‐products (RAGE). Activation of these receptors is involved in the progression of renal fibrosis; however, the role of S100A8/A9 herein remains unknown. Therefore, we analysed S100A8/A9 expression in patients and mice with obstructive nephropathy and subjected wild‐type and S100A9 knock‐out mice lacking the heterodimer S100A8/A9 to unilateral ureteral obstruction (UUO). We found profound S100A8/A9 expression in granulocytes that infiltrated human and murine kidney, together with enhanced renal expression over time, following UUO. S100A9 KO mice were protected from UUO‐induced renal fibrosis, independently of leucocyte infiltration and inflammation. Loss of S100A8/A9 protected tubular epithelial cells from UUO‐induced apoptosis and critical epithelial–mesenchymal transition steps. In‐vitro studies revealed S100A8/A9 as a novel mediator of epithelial cell injury through loss of cell polarity, cell cycle arrest and subsequent cell death. In conclusion, we demonstrate that S100A8/A9 mediates renal damage and fibrosis, presumably through loss of tubular epithelial cell contacts and irreversible damage. Suppression of S100A8/A9 could be a therapeutic strategy to halt renal fibrosis in patients with chronic kidney disease.
Keywords: damage‐associated molecular patterns, innate immunity, renal fibrosis, S100 proteins, tubular integrity
Introduction
Fibrotic diseases, including progressive renal diseases, lead to loss of function and organ failure. They represent a major socioeconomic burden and account for at least one‐third of deaths worldwide 1. Renal fibrosis is the final common pathway leading to end‐stage renal disease (ESRD), a condition for which no effective treatments exist except for life‐long dialysis or renal transplantation 2. The pathophysiological mechanisms driving the loss of renal function involve four cellular protagonists: myofibroblasts, tubular epithelial cells (TECs), immune cells and endothelial cells which, upon (mal)adaptive activation, induce the progression of tubulo‐interstitial fibrosis 3. Although progress has been made in understanding the molecular mechanisms underlying the development of fibrosis, the failure to limit this process is undeniable. Thus, new avenues need to be explored in order to offer a therapeutic potential for preventing renal fibrosis.
Calprotectin, or the S100A8/S100A9 protein complex, belongs to the S100 calcium‐binding protein family. This heterodimer protein is expressed and released by activated phagocytes, mainly neutrophils and macrophages, and has been shown to induce cytoskeleton reorganization 4, chemotaxis 5 and cytokine expression 6, 7. Apart from the above‐mentioned intracellular functions, S100A8/A9 is also released upon tissue injury, thereby acting as a damage‐associated molecular pattern (DAMP), which mediates the activation of the inflammatory response 8, 9. In the context of obstructive nephropathy, damaged cells release DAMPs such as S100A8/A9 to alert the immune system 10, 11. In response to the insult, S100A8/A9 functions as an endogenous ligand which binds to pattern recognition receptors (PRRs), including Toll‐like receptor (TLR)‐4 12, 13 and the receptor for advanced glycation end‐products (RAGE) 14, 15. Both receptors are expressed by macrophages and TECs following ureteral obstruction 16, 17, which can initiate the inflammatory response and are involved in processes related to tissue repair. Also, chronic inflammation may perpetuate tissue injury leading to the development of fibrosis 3. Indeed, several studies have demonstrated that TLR‐4 and RAGE represent key factors of chronic kidney disease (CKD) progression through modulation of interstitial fibrosis 17, 18. As these receptors are crucial for host defence it might be more interesting to target their ligands instead. Thus, we investigated the role of their shared ligand S100A8/A9 in the pathogenesis of renal fibrosis. To assess the contribution of S100A8/A9 in the progression of renal fibrosis we subjected wild‐type (WT) and S100A9 knock‐out (KO) mice to UUO and determined its expression, location and function.
Materials and methods
Patients
Renal biopsies (n = 3) were obtained from patients diagnosed with obstructive hydronephrosis, characterized by extensive fibrosis and tubular atrophy or healthy renal tissue, at the Academic Medical Center (University of Amsterdam), as described previously 19. All biopsies were taken for diagnostic purposes only. For the present study, only left‐over biological material was used, delinked from patient records, and as such was not subjected to any requirement for ethical review or approval according to Dutch law when patients have made no objection (Article 7:467 BW Book 7). We have only used the material of patients with no objection.
Experimental animals and procedure
The Institutional Animal Care and Use Committee of the University of Amsterdam approved all experiments for the animal study, in compliance with the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines (NC3Rs). The study was designed with two experimental groups: (1) C57Bl/6 WT controls (n = 8) and (2) S100A9 KO animals (n = 8) and four time‐points (from days 1, 3, 7 and 14 of killing) for each experimental group. Each experimental group was divided into two cages of three and five animals. The total number of mice for the experimental group was 32. Genetic deletion of S100A8 leads to embryonic lethality 20,21. We therefore used S100A9‐deficient mice that lack functional calprotectin complex and display almost undetectable levels of S100A8 protein. These mice were generated as described previously 21 and back‐crossed to a C57Bl/6 genetic background. Animals were bred in the animal facility of the Academic Medical Center (AMC) in Amsterdam, the Netherlands. Eight to 10‐week‐old male mice were used in the experiments. Age‐ and sex‐matched WT C57Bl/6 mice were purchased from Charles River Laboratories (Cologne, Germany). Mice weighed approximately 25 g/mouse. Animals were kept in standard environmental conditions (temperature, humidity, ventilation, light/dark cycle), housed in specific pathogen‐free conditions (SPF) with ad libitum access to water and food, and allowed to acclimatize for a week before starting the experiment. WT C57BL/6 and S100A9 KO mice were subjected to progressive renal injury by UUO, as described previously 19. Briefly, the right ureter was ligated (near the ureteropelvic junction) with suture (6.0 Tyco healthcare) under 2·5% isoflurane‐induced anaesthesia and oxygen (via inhalation) through an abdominal incision. The surgical procedure was carried out in the morning under the laminar flow cabinet with a temperature‐controlled heating pad. Upon completing surgery, muscle and skin layers were closed with surgical sutures (6.0, Tyco healthcare). Fifty µg/kg buprenorphine was administered through a subcutaneous injection for analgesic purposes (Temgesic, Schering‐Plough, Kenilworth, NJ, USA). Animals were killed via cardiac exsanguination followed by cervical dislocation at days 1, 3, 7 and 14 post‐surgery. Sham mice were killed at day 1 post‐UUO. Contralateral/unobstructed left kidneys were also used as controls.
RNA isolation and reverse transcriptase–polymerase chain reaction (RT–PCR)
Total RNA was isolated from snap‐frozen renal tissue using Trizol reagent (Invitrogen, Waltham, MA, USA), according to the manufacturer’s protocol. RNA was converted into cDNA by the use of oligo‐dT as a primer. Gene expression was analysed by reverse transcriptase‐polymerase chain reaction (RT–PCR) with SYBR green PCR master mix on a Lightcycler 480 (Hoffmann‐Roche, Basel, Switzerland). Relative expression was analysed using LinRegPCR (developed by Hearth Failure Research Center, University of Amsterdam, the Netherlands). Gene expression was normalized to mouse TATA box‐binding protein (Tbp) housekeeping gene, n = 7/8 animals per group; see Supporting information, Table S1 for primer sequences.
Plasma biochemical analysis
Plasma levels of creatinine were measured by standard autoanalyser methods at our hospital research services.
Enzyme‐linked immunosorbent assay (ELISA) and immunoblot
In order to measure renal S100A8/A9 and transforming growth factor (TGF)‐β1 protein, snap‐frozen kidney (n = 7/8) tissues were homogenized in Greenberger lysis buffer (150 mM NaCl, 15 mM Tris, 1 mM MgCl2 pH 7.4, 1 mM CaCl2, 1% Triton X‐100 and 1% protease inhibitor cocktail (Sigma‐Aldrich, Zwijndrecht, the Netherlands). The S100A8/A9 Heterodimer DuoSet and TGF‐β1 ELISA kit (R&D Systems, Minneapolis, MN, USA) were used according to the manufacturer’s protocol.
Snap‐frozen kidneys or cell lysates were used for immunoblotting (n = 2/4). Protein lysates were obtained from snap‐frozen kidney tissue or primary TECs derived from in‐vitro assays. Tissue and cells were lysed in radioimmunoprecipitation assay (RIPA) buffer [50 mM Tris pH 7.5, 0·15 M NaCl, 2 mM ethylenediamine tetraacetic acid (EDTA), 1% deoxycholic acid, 1% NP‐40, 4 mM sodium orthovanadate, 10 mM sodium fluoride], supplemented with 1% of protease inhibitor cocktail (Sigma‐Aldrich, Zwijndrecht, the Netherlands). Lysates were loaded on a 4–12% Nupage gel and blotted onto a polyvinylidene difluoride (PVDF) membrane. After blocking a specific signal, blots were incubated overnight at 4°C with different antibodies, as listed in Supporting information, Table S2. Blots were incubated with horseradish peroxidase‐conjugated secondary antibodies and detected with enhanced chemiluminescence (ECL) (Pierce, Waltham, MA, USA).
Immunostaining
Renal tissues were fixed in 10% formalin for 24 h, processed and paraffin‐embedded. For immunohistochemical staining, 4‐µm‐thick sections of murine renal tissues (n = 7/8) or human biopsies (n = 3) were treated for 30 min with 0·25% pepsin in 0·1 M HCl at 37°C (for Ly6G) or boiled for 10 min in 10 mM citrate (pH 6.0) (other antibodies), incubated overnight with different primary antibodies, as described in Supporting information, Table S2, and developed using diaminobenzidine (DAB) (Sigma). For collagen staining, slides were incubated with 0·2% Picro Sirius Red (PSR) solution (pH 2.0) for 1 h followed by incubation within 0·01 M HCl. Periodic acid–Schiff diastase (PAS‐D) was used to quantify the number of intact tubules, based on morphology, dimensions and brush border presence, as described previously 2. To quantify the number of apoptotic and proliferating TECs only tubules (not interstitial cells) surrounding glomeruli were included in the count, as shown by the white drawings in the picture. The number of intact tubules and those positive for cleaved caspase‐3 or Ki67 were counted within 10 non‐overlapping high‐power fields (HPF) (×40 magnification) in a blinded manner. The amount of positive staining for F4/80, alpha smooth muscle actin (αSMA), collagen I, PSR, intercellular adhesion molecule 1 (ICAM‐1), S100A8 and S100A9 was quantified with ImageJ software, Fiji (National Institutes of Health, Bethesda, MD, USA), a computer‐based imaging analysis for reliable biomarker quantitation which is applied widely for tissue‐based research.
For sequential immunohistochemistry, sections were labelled and stained with NovaRed, as described previously 22. After each staining slides were acquired on a digital slide scanner (IntelliSite Pathology Ultra Fast Scanner; Philips, Eindhoven, the Netherlands). Afterwards, coverslips were removed and the sections were stripped by incubation for 30 min in 1 M Tris–HCl (pH 7.5) supplemented with 2% (v/v) sodium dodecyl sulphate and 0·7% (v/v) β‐mercaptoethanol at 50°C, followed by rinsing with tap water. Complete removal of the stain was ensured by visual inspection. Three sequential stainings (mouse: S100A8, S100A9 and Ly6G/F480; human: S100A8/S100A9, CD15 and CD68) were performed on the same section. Overlay images were obtained as described previously by our group 22.
For immunofluorescence staining, paraffin‐embedded tissues from T14 post‐UUO were incubated with biotin–dolichos biflorus agglutinin (DBA: collecting duct marker) and lotus tetragonolobus lectin (LTL: proximal tubule marker) followed by streptavidin fluorescein isothiocyanate (FITC). Primary antibodies incubation followed the lectin staining. Rat‐anti‐S100A8 and S100A9 primary antibodies were detected by rabbit anti‐rat Texas Red. Nuclei were stained with Hoechst. Pictures were taken with a fluorescence light microscope (Leica, Wetzlar, Germany; magnification ×40).
Reagents were used according to the manufacturer’s protocol.
In‐vitro assays
For in‐vitro assays, primary, immortalized proximal TECs (IM‐PTEC) and polarized TECs [Madin–Darby canine kidney cells (MDCK)] were used. Primary TECs were isolated from kidneys of C57Bl/6 WT mice (n = 4), as described previously 23. IM‐PTECs were cultured in hexokinase 2 (HK2) medium supplemented with interferon gamma at 33°C. A week before the experiment, IM‐PTEC cells were transferred to a 37°C incubator in order to lose SV40 expression 24. MDCK cells were cultured on collagen‐coated coverslips in HK2 medium. Cells were stimulated with different concentrations of recombinant S100A8/A9 (rS100A8/A9) (kindly provided by T. Vogl) and/or recombinant TGF‐β1 (rTGF‐β1) (Pepscan, Lelystad, the Netherlands), as described in the figure legends, for 24 h.
Cell death assays were performed as follows. Cells were detached with trypsin, washed once with phosphate‐buffered saline (PBS) followed by washing with annexin V buffer [500 ml: 1·19 g HEPES, 4·4 g NaCl, 0·19 g KCl, 0·1 g CaCl2, 0·1 g MgCl2, 1 ml/ml glucose and 0·5% bovine serum albumin (BSA), pH 7.3]. Subsequently, cells were incubated with annexin V for 20 min on ice in the dark. Propidium iodide (PI) or To‐Pro3 (Thermo Fisher, Fremont, CA, USA) was added to the cells prior to acquisition. Cells were acquired on a fluorescence activated cell sorter (FACS)Canto (Becton Dickinson, San Jose, CA, USA) and analysed with Flow‐Jo software (TreeStar, Inc., Ashland, OR, USA).
The activity of caspase‐3 was measured in cell lysates, using the fluorogenic substrate Ac‐DEVD‐AMC (Enzo Life Sciences, Exeter, UK), in the caspase assay buffer [HEPES 20 mM, dimethyl [3‐( propyl)] azaniumyl propane‐1‐sulphonate (CHAPS) 5 mM, dithiothreitol (DTT) 5 mM, EDTA 5 mM]. Fluorescence was measured with a 360‐nm excitation wavelength and 460‐nm emission wavelength.
For immunofluorescence on MDCK cells cultured on coverslips, cells were fixed and permeabilized before incubation with primary antibodies followed by AlexaFluor 488‐conjugated secondary antibody. Pictures were taken with a fluorescence light microscope (Leica; magnification ×40).
Statistics
Comparisons between two groups were analysed using the Mann–Whitney U‐test or between more than two groups with the Kruskal–Wallis test, unless mentioned otherwise in the figure legend. For in‐vitro experiments, comparison between two groups was analysed using the two‐tailed Student’s t‐test. Values are expressed as mean ± standard error of the mean (s.e.m.). P‐values < 0·05 were considered statistically significant.
Results
Increased S100A8/A9 expression in human biopsies and murine renal tissue with obstructive nephropathy
We first investigated the expression of S100A8 and S100A9 in renal biopsies of patients with obstructive hydronephrosis. As a control we used the healthy area in renal tissue derived from nephrectomy for malignancy. Using immunohistochemistry (IHC) we observed that S100A8 and S100A9 expression is increased during obstructive nephropathy and is localized to the tubulo‐interstitial compartment (Fig. 1a). It is noteworthy that non‐myeloid cells such as tubular cells did not show any positivity for S100A8/A9 as described previously after stress conditions 8. The S100A8/A9‐positive cells were identified as granulocytes and not macrophages, as displayed by co‐localization (overlay displayed in yellow and highlighted with arrow) of S100A8/A9 (red) with CD15 (green), a marker for granulocytes but not with CD68 (macrophage marker: blue) (Fig. 1b).
Figure 1.

Human and murine S100A8/A9 expression during obstructive nephropathy. (a) Immunohistochemistry for human S100A8 and S100A9 on healthy tissue (CTR) and from kidney biopsies of patients with obstructive hydronephrosis (ON). (b) Representative examples of original immunostaining and composite overlays for S100A8 or S100A9 (red), CD15 (green) and CD68 (blue) on obstructive nephropathy biopsies. Composite images, obtained with Image J, reveal only the triple overlay between S100A8/S100A9 and CD15 (yellow cells and arrow) (magnification ×40). (c) Representative pictures of murine S100A8/A9 staining in kidney sections from wild‐type (WT) and S100A9 knock‐out (KO) mice. (d) Quantification of S100A9 in contralateral kidneys (CL) (grey bar) and WT mice (white bars) upon 1, 3, 7 and 14 days of unilateral ureteral obstruction (UUO). (e) Quantification of S100A8 in CL kidneys and upon 1, 3, 7 and 14 days of UUO in sham WT and S100A9 KO mice. (f) Murine S100A8/A9 protein complex levels in CL kidneys or following 1 and 14 days of UUO in WT mice as measured by enzyme‐linked immunosorbent assay (ELISA). Protein expression was corrected for total protein levels in renal tissue. (g) Representative examples of original immunostaining and composite overlays for S100A8 (red), S100A9 (green) and Ly‐6G or F480 (blue) in WT mouse kidney after 14 days of UUO. Overlay pictures were obtained by sequential immunostaining technique as described in Material and methods. Co‐localization of murine S100A8/A9 are shown in yellow. Triple overlay is shown in pink/purple colour and indicated with pink arrows (S100A8, S100A9 and LY6G) (magnification ×40). Graph data are mean ± standard error of the mean (s.e.m.). #P < 0·05 versus WT at the same time‐point, *P < 0·05, **P < 0·005, ***P < 0·0005 versus CL unobstructed kidney. Scale bar 200 µm; n = 3 for human data. For statistical analysis of murine data the Mann–Whitney U‐test was used for comparison between two groups; n = 7/8 mice per group.
Next, we evaluated expression and localization in the experimental model of obstructive nephropathy UUO, which mimics the various stages of progressive renal injury and fibrosis 25. Similar to human staining, in murine kidney we detected S100A8‐ and S100A9‐ positive cells mainly within the interstitial compartment (Fig. 1c). Digital quantification of stained tissue revealed an increased expression of S100A8/A9 over time (Fig. 1d,e). Staining for S100A8 was almost undetectable in S100A9 KO mice (Fig. 1c,e). As S100A8/A9 functions as a heterodimer, we measured this by enzyme‐linked immunosorbent assay (ELISA). S100A8/A9 complex is expressed significantly 14 days after surgery, compared to contralateral tissue (Fig. 1f).
As in the human study, sequential immunostaining was used to determine the cellular source of S100A8/A9 expression in kidney post‐UUO at day 14. We found that S100A8 (red) co‐localizes with S100A9 (green) (overlay in yellow) suggesting that the functional heterodimer is present. Moreover, and in line with human data, the complex co‐localizes with the granulocyte marker Ly6G (blue) (overlay: pink positive cells highlighted with pink arrow) but not with the macrophage marker F480 (blue) (Fig. 1g). Of note, staining for granulocyte influx (Ly6G) in renal tissue was similar between WT and S100A9 KO mice 1 and 14 days following UUO (WT versus S100A9 KO mice, day 1: 1·1 ± 0·3 versus 1.9 ± 0·4 and day 14: 7 ± 1·8 versus 8·6 ± 4·4% positive staining/HPF). The small percentage of S100A8/A9‐positive cells, which do not express the Ly6G marker, appears to be positive for DBA but not for LTL (Supporting information, Fig. S1). Together, these human and experimental data suggest a potential role for S100A8/A9 in progressive renal injury.
S100A9 deficiency dampens renal fibrosis independently of leucocyte infiltration
To directly assess the contribution of S100A8/A9 to renal interstitial fibrosis, we analysed the presence of α‐SMA‐positive myofibroblasts and collagen deposits in WT and S100A9 KO mice after UUO. We have described previously that, in untreated conditions, levels of α‐SMA, collagen‐1 and macrophage polarization markers were similar between WT and KO mice 21.
Differences were found at time‐points where we observed the highest expression of the S100A8/A9 monomer (such as days 7 and 14). We did not detect any differences in these parameters at days 1 and 3 following UUO (data not shown). Seven days following UUO, kidneys of S100A9 KO mice showed less accumulation of myofibroblasts compared to WT mice, whereas no differences were observed at day 14 (Fig. 2a). A reduction of collagen deposition, detected by IHC, was observed in S100A9 KO mice compared to WT at 7 and 14 days of UUO (Fig. 2b). The latter finding was also verified by PSR staining, which confirmed that KO mice have reduced collagen deposits 14 days post‐UUO (Fig. 2c).
Figure 2.

Renal fibrosis in wild‐type (WT) and S100A9 knock‐out (KO) mice during unilateral ureteral obstruction (UUO). Renal fibrosis as displayed by representative pictures and quantification of (a) α‐smooth muscle actin (SMA), (b) collagen 1 and (c) Picro Sirius Red (PSR) staining on renal tissue slides from WT and S100A9 KO mice 7 and 14 days after UUO. (d,e) Transcript expression of pro‐fibrotic genes Pdgfa and Col1a1 measured by reverse transcriptase–polymerase chain reaction (RT–PCR). Data are expressed relative to the housekeeping gene Tbp in WT and S100A9 KO mice 7 and 14 days after UUO. (f) Transforming growth factor (TGF)‐β protein detected by enzyme‐linked immunosorbent assay (ELISA) in contralateral (CL) and obstructed kidney from WT and S100A9 KO mice, 14 days post‐UUO. (g) Plasma levels of creatinine in WT and S100A9 KO animals, 7 and 14 days after UUO. HPF = high‐power field. Magnification ×20. The Mann–Whitney U‐test was used for comparisons between two groups; n = 7/8 mice per group. Graph data are mean ± standard error of the mean (s.e.m.). *P < 0·05, **P < 0·005, ***P < 0·0005 versus WT at the same time‐point. #P < 0·005 compared to WT at T7. Scale bar 200 µm.
The reduced extent of fibrosis in the S100A9 KO animals also affected the expression of the profibrotic growth factor platelet‐derived growth factor (Pdgfa) and collagen‐1 genes (col1a1), particularly 14 days after UUO (Fig. 2d,e). During progression of fibrosis, particularly 14 days upon UUO, TGF‐β1 is expressed and activated in WT mice, whereas in S100A9 KO animals appears to be significantly decreased (Fig. 2f). The rescue in renal fibrosis was accompanied by a functional renal improvement, as shown by decreased levels of creatinine (Fig. 2g).
Sustained inflammation is a hallmark of progressive renal fibrosis 3. In particular, macrophages modulate tubulo‐interstitial damage after UUO 26. Accumulation of F4/80+ macrophages and the transcript expression of proinflammatory mediators such as C‐C motif chemokine ligand 2 (CCL2), interleukin (IL)‐6 and tumour necrosis factor (TNF)‐α was comparable between WT and S100A9 KO mice at days 7 and 14 post‐UUO (Fig. 3a–d). S100A8/A9 can modulate macrophage polarization 21, 27. However, we found no differences in the expression of M1‐ and M2‐differentiated macrophages markers (Nos2, Irf5, Ly6c and Arg1, Irf4 and Mrc1, respectively) between WT and KO mice (Fig. 3e,f).
Figure 3.

Inflammatory parameters in WT and S100A9 KO mice. (a) Renal macrophages accumulation shown as percentage of F480 positive area detected by IHC, in renal tissues 7 and 14 days post‐ unilateral ureteral obstruction (UUO). Next, transcript expression in renal tissue of (b) Ccl2 (the gene for MCP‐1), (c) Il6 and (d) Tnfa measured by reverse transcriptase–polymerase chain reaction (RT–PCR). (e) Transcript expression in renal tissue of M1 markers, Nos2, Irf5, Ly6c and (f) M2 macrophage markers, Arginase‐1, Irf4, Mrc1 measured by reverse transcription–polymerase chain reaction (RT–PCR). Values are relative to the housekeeping gene Tbp. Data are expressed as mean ± standard error of the mean (s.e.m.); n = 7/8 samples per group.
Altogether, these results suggest that S100A8/A9 has a detrimental effect on the development of UUO‐induced renal fibrosis, which was not associated with a difference in inflammatory cytokine response or modulation of gene expression, indicative of macrophage polarization.
S100A9 deficiency preserves tubular epithelial cells integrity following UUO
Next, we evaluated whether differences in fibrosis between WT and S100A9 KO mice could be ascribed to an effect on TECs injury. Thus, we analysed TECs apoptosis, proliferation and morphology at days 7 and 14 post‐ UUO. Compared to WT mice, S100A9 KO mice display decreased tubular apoptosis, as shown by cleaved caspase‐3 positive tubular cells (Fig. 4a,d). In addition, the proliferation of tubular cells, as verified by Ki67 positivity, was increased in S100A9 KO mice compared to WT animals (Fig. 4b,e). These findings were corroborated by the presence of an increased number of intact tubules in S100A9 KO mice, as detected by the presence of brush border and regular morphology with PAS‐D staining (Fig. 4c,f). Epithelial mesenchymal transition (EMT) occurs in TECs in response to injury and can lead to the progression of tubulo‐interstitial fibrosis 3, 25. Critical molecular events in EMT are characterized by loss of expression of adhesion molecule E‐cadherin and by the induction of the transcription factor Twist 28. Compared to WT mice, S100A9 KO mice display increased expression of the E‐cadherin transcript 14 days post‐surgery (Fig. 4g). E‐cadherin expression is regulated negatively by Twist, which was decreased in S100A9 KO animals compared to WT upon 14 days of UUO (Fig. 4h). Given the decreased activation of the key transition steps leading to EMT, together with the development of fibrosis, we investigated whether these observations correlated with the level of renoprotective cytokine IL‐10, shown recently to have anti‐fibrotic effects in the context of UUO 29. Indeed, IL‐10 was increased significantly in S100A9 KO mice compared to WT 14 days after UUO (Fig. 4i). Altogether, these data suggest that S100A9 deficiency ameliorates renal fibrosis by preserving tubular health, possibly via the suppression of critical molecular events in EMT.
Figure 4.

Tubular injury and epithelial mesenchymal transition (EMT in wild‐type (WT) and S100A9‐deficient mice, 7 and 14 days post‐unilateral ureteral obstruction (UUO). (a,d) Tubular apoptosis as displayed by representative pictures and quantification of cleaved caspase‐3 positive tubules on renal tissue slides from WT and S100A9 knock‐out (KO) mice. (b,e) Tubular proliferation as displayed by representative pictures and quantification of Ki‐67. No interstitial Ki‐67‐positive cells were included in the count. (c,f) Periodic acid–Schiff‐diastase (PAS‐D) staining of renal tissue was used to quantify the number of healthy tubules (by presence of brush border) in WT and S100A9 KO mice 7 and 14 days after UUO. Only tubules surrounding glomeruli were considered for the above analysis. White drawing in the pictures show an example of tubular cells included in the count. The number of caspase‐3, Ki67‐positive and healthy tubular epithelial cells (TECs) (measured by PAS‐D) were counted in 10 non‐overlapping high‐power fields (HPFs), having glomerular cells as reference, in a blind manner, with a ×40 magnification. (g–i) Transcript expression of E‐cadherin, Twist and Il10 measured by reverse transcriptase–polymerase chain reaction (RT–PCR) in WT and S100A9 KO, 7 and 14 days upon UUO. Values are normalized to the housekeeping gene Tbp. The Mann–Whitney U‐ test was used for comparison between two groups; n = 7/8 mice per group. Graph data are expressed as mean ± standard error of the mean (s.e.m.). *P < 0·05, **P < 0·005, versus WT at the same time‐point. Scale bar 200 µm.
S100A9 deficiency is associated with down‐regulation of RAGE and its interacting receptor ICAM‐1
S100A8/A9 can bind either TLR‐4 or RAGE receptors, which are both up‐regulated in epithelial cells following UUO 17, 18. We therefore analysed and normalized the expression of TLR‐4 and RAGE protein in murine kidneys of WT and S100A9 KO mice 14 days post‐UUO, as more consistent results were obtained at this time‐point. TLR‐4 and RAGE proteins showed a similar down‐regulated pattern in kidney lysates after UUO in the absence of S100A9, with statistical significance for RAGE (Fig. 5a–c).
Figure 5.

Expression of S100A8/A9 receptors, Toll‐like receptor (TLR)‐4 and receptor for advanced glycation end‐products (RAGE). (a–c) Expression of RAGE and TLR‐4 protein measured by Western blot. Quantification of RAGE and TLR‐4 in wild‐type (WT) (n = 2) and knock‐out (KO) (n = 4) kidney lysates from day 14 after unilateral ureteral obstruction (UUO). Values were normalized to the levels of β‐actin. Statistical difference were analysed by two‐tailed Student’s t‐test. (d,e) Intercellular adhesion molecule 1 (ICAM‐1) transcript and protein expression as measured by reverse transcriptase–polymerase chain reaction (RT–PCR)and immunohistochemistry (IHC), respectively, in tissue of WT and KO mice, 14 days after UUO; n = 5 mice per group. (e) Representative pictures of ICAM‐1 IHC. Percentage of positive staining was measured by ImageJ software. The Mann–Whitney U‐test was used for comparison between these groups. Graph data are mean ± standard error of the mean (s.e.m.). *P < 0·05, **P < 0·005 versus WT. Scale bar 200 µm.
As, together with intracellular adhesion molecule‐1 (ICAM‐1), RAGE may mediate interstitial fibrosis by modulating epithelial integrity during UUO 17, we investigated the expression of ICAM‐1. Our results show that besides RAGE, ICAM‐1 is also reduced in KO kidneys 14 days post‐UUO compared to WT tissue at mRNA and protein levels (Fig. 5d,e). It is conceivable that the S100A8/A9 may induce tubular injury via RAGE and its interacting receptor ICAM‐1.
Recombinant S100A8/A9 directly affects TECs de‐differentiation and cell death in vitro
In order to unravel the mechanism by which S100A8/A9 contributes to tubular injury, TECs were stimulated with different concentrations of recombinant S100A8/A9 protein. As previous studies have shown that S100A8/A9 impairs endothelial cell integrity by down‐regulation of cell junction protein 30, 31, which leads to cell death, we measured the expression of cell junction protein zonula occludens‐1 (ZO‐1) and adhesion molecule E‐cadherin in TECs stimulated with a low concentration of S100A8/A9. Our results show that S100A8/A9 induces a profound down‐regulation of ZO‐1 protein expression and a trend in E‐cadherin decrease, which was also confirmed in a polarized cellular system of TECs (Fig. 6a and Supporting information, Fig. S2). Moreover, rS100A8/A9 affects not only cell–cell junction, but the expression of mitotic cyclin B1 (Fig. 6a), the latter suggesting a proliferation arrest. Of note, the cell‐cycle arrest did not induce full EMT in TECs, measured by expression of α‐SMA (data not shown).
Figure 6.

Effect of extracellular S100A8/A9 on tubular epithelial cells. (a) Western blot analysis of primary tubular epithelial cells (TECs) isolated from four wild‐type WT) mice (Charles River) and stimulated with a low concentration of rS100A8/A9 (5 µg/ml) for 24 h in HK2 medium. Protein expression of ZO‐1, E‐cadherin and cyclin B1 are calculated relatively to the levels of tubulin. (b) Fluorescence activated cell sorter (FACS) plots and histograms relative to cell death measured by annexin V/propidium iodide (PI) staining in stimulated immortalized proximal TEC (IM‐PTEC) cells with S100A8/A9 (10, 50 and 100 µg/ml) for 24 h in hexokinase 2 (HK2) medium. The percentage of late apoptotic cells/necrotic (double‐positive) are showed in the graph. (c) Representative plots of IM‐TEC stimulated with S100A8/A9 (50 µg/ml) in the presence or absence of the Q‐VD‐OPh hydrate (ApexBio), a pan‐caspase inhibitor (20 µM). (d) Representative plots of IM‐TEC stimulated with rS100A8/A9 (100 µg/ml) and/or recombinant human transforming growth factor (rhTGF)‐β1 (20 ng/ml). Cells were treated for 24 h and harvested for annexin V/PI or To‐Pro3 staining. FACS data are representative of three independent experiments. Statistical difference were analysed by two‐tailed Student’s t‐test. Data are expressed as mean ± standard error of the mean (s.e.m.). *P < 0·05, **P < 0·005, ***P < 0·0005 versus unstimulated control.
To study whether extracellular S100A8/A9 can affect cell death, TECs were stimulated with increasing concentrations of rS100A8/A9 and apoptosis/necrosis was measured by FACS analysis with annexin V/PI staining. S100A8/A9 induced late apoptosis/necrosis in TECs, as shown by an increased percentage of PI/annexin V+ cells in a concentration‐dependent manner (Fig. 6b). This cytotoxic effect of S100A8/A9 was not reversed by treatment with a Pan‐caspase inhibitor Q‐VD‐OPh hydrate (QVD), suggesting that S100A8/A9 induces a caspase‐independent cell death, most probably necrosis, as observed by PI uptake (Fig. 6c). In support of this observation, we found that caspase‐3 activity was not affected by incubation with rS100A8/A9 or upon ligand activation of TLR‐4 or RAGE receptor (Supporting information, Fig. S3).
However, to mimic further a UUO‐like model in vitro, we co‐stimulated cells with rTGF‐β1 and rS100A8/A9 and evaluated the effect on TEC cell death. Surprisingly, we noticed that the fibrotic trigger in combination with S100A8/A9 leads to increased early apoptosis and not necrosis, as observed by increased annexin V+ cells (Fig. 6d).
Altogether, these in‐vitro data indicate that S100A8/A9 induces polarity changes in TECs which might disrupt the interaction between epithelial cells, driving subsequent cell death and tubular atrophy during progressive renal fibrosis.
Discussion
CKD is a pathological condition with different aetiologies characterized by a progressive loss of nephrons and renal fibrosis. Treatments to prevent renal fibrosis still rely upon regimes targeting the underlying disease processes, such as diabetes and hypertension 1. Identifying novel targets which delay, arrest or reverse the progression of tissue fibrosis may lead to treatment opportunities for patients suffering from CKD. Increasing evidence suggests that DAMPs released during tissue injury, together with the innate immune receptors involved in their recognition 9, contribute to the development of renal fibrosis 10, 11. However, the role of the damage molecule S100A8/A9 in the pathogenesis of obstructive nephropathy has not yet been unravelled. This study provides evidence that S100A8/A9 protein may emerge as a target for novel therapeutic interventions to preserve parenchymal integrity as chronic fibrotic disease progresses. We found that S100A8/A9 mediates renal fibrosis, activation of critical molecular events in EMT and tubular apoptosis independently of leucocyte infiltration in the kidney after UUO. In vitro, we showed that S100A8/A9 has a deleterious effect on TEC morphology, by inducing loss of cell junction proteins and arrest of cell proliferation, possibly driving subsequent irreversible tubular damage. These changes in tubular morphology result eventually in cell death by apoptosis, when S100A8/A9 is combined with a pro‐fibrotic trigger such as TGF‐β1.
S100A8/A9 is a critical player during inflammatory responses 32. Previous studies have shown that, in human diseases, S100A8/A9 can be detected in serum, aspirates or faeces of patients with rheumatoid arthritis 33, acute rejection 34, 35, inflammatory bowel disease 36, lung disease 37, systemic sclerosis 38 and atherosclerosis 39. In the context of renal fibrosis, we are the first to show that S100A8/A9 expression is increased in patients with obstructive nephropathy and localizes uniquely to interstitial granulocytes and not to other parenchymal cells, such as epithelial cells 40. These human findings were corroborated by the experimental data where we observed increased expression of S100A8/A9 in WT mice following UUO, and its localization was similar to that observed in human samples. Despite similar experimental conditions, Fujiu et al. 27, showed that S100A8/A9 expression is high in collecting duct cells and that expression peaks at day 1 post‐UUO, whereas in our experiment S100A8/A9 seems to be expressed mainly by granulocytes and only with a low percentage in collecting duct cells, with a peak at day 14 post‐UUO. These contrasting results may be related to differences in the technical method used to identify these cells. We performed immunohistochemical staining, whereas Fujiu et al. looked at the transcript expression of sorted cells from UUO kidney. The results of two techniques may not be fully comparable, as protein and mRNA might have discordant results in similar pathological conditions 41.
Although we detected S100A8/A9 expression mainly on infiltrating granulocytes, mice lacking S100A9 displayed similar granulocyte numbers compared to WT mice, as shown previously by our group in the acute model of injury 21, suggesting a limited role of S100A8/A9 in granulocyte infiltration in both acute and chronic models of renal injury. Nonetheless, the role of granulocytes in the progression of renal fibrosis is not as pronounced as the role of macrophages 42. Instead, the latter play a pivotal role in the development of tubulo‐interstitial injury, due to the activation of an excessive inflammatory response 26, 43. Previously, in renal ischaemia reperfusion (IR), we showed a beneficial role of S100A8/A9 in controlling macrophage‐mediated renal repair by preventing excessive M2 polarization and renal fibrosis 21. Supporting this study, Rekers et al. showed that high levels of S100A8/A9 correlated with improved graft outcome after kidney transplantation 35. Thus, we hypothesized that S100A8/A9 would dampen macrophage‐induced inflammation and the development of renal fibrosis following UUO. Surprisingly, in sharp contrast to the results obtained in renal IR and allograft rejection, we found that S100A9 KO mice were protected against renal fibrosis, independently of the activation of the inflammatory response, macrophage infiltration and polarization, which suggests a deleterious role for S100A8/A9 in renal fibrogenesis.
In the UUO model, one study demonstrated that Klf5 controls macrophage polarity via S100A8/A9, thereby controlling tissue remodelling and limiting fibrosis 27. These findings were obtained in mice aploinsufficient for Klf5 which, although not specific for S100A8/A9, is known to regulate other cellular processes such as growth and differentiation 27. Apparently, S100A8/A9 is a beneficial player in the progression of acute renal disease, but shows contrasting results in the context of obstructive nephropathy. We speculate that in the renal IR model the functional S100A8/A9 signalling in non‐parenchymal cells is necessary to recognize the initial damage from ischaemic cells and initiate a proper wound‐healing response from macrophages. Indeed, the aberrant innate immune response observed in the KO animals after IR may be responsible for an altered wound‐healing process with progression to renal fibrosis.
If S100A8/A9 protein reduces the risk of maladaptive renal repair following renal IR, low levels of the protein during the progression of renal fibrosis may prevent perpetuation to irreversible damage. This dual role of S100A8/A9 might be dependent upon the primary insult driving the progression of renal fibrosis. In the UUO model, S100A8/A9 signalling in immune cells seems to be dispensable for the progression of renal fibrosis, as demonstrated in mice over‐expressing S100A12/A8/A9 specifically in myeloid cells and subjected to UUO ligation. These mice displayed no differences in interstitial inflammation and fibrosis/tubular atrophy in the kidney, suggesting a dispensable role for inflammatory cell‐associated S100A8/A9 in renal fibrosis 44. Interestingly, similar to our study, a study on cardiac fibrosis, showed that inhibition of S100A8/A9 via a neutralizing antibody suppressed angiotensin II (AngII)‐induced perivascular and interstitial fibrosis 45.
This would suggest that, in the absence of S100A8/A9, other DAMPs are released during chronic damage which may compensate for the activation of the inflammatory response. S100A8/A9 signals via RAGE and TLR‐4. Mice deficient for both receptors show a phenotype similar to that of S100A9 KO mice, namely decreased fibrosis independently of leucocyte infiltration and reduced nuclear factor kappa B (NF‐βB) activation 17, 18. Thus, it appears that S100A8/A9 and its interacting receptors modulate the extent of fibrosis via pathological mechanisms activated in parenchymal cells, instead of regulating the inflammatory response 46. Hence, blocking DAMPs might be a great alternative for targeting the multiple receptors associated with immunopathology, as it will not hinder pathogen detection.
Following UUO, TECs become injured and start to lose their functionality. As a survival mechanism, TECs start an EMT programme with myofibroblast recruitment and subsequent collagen deposits 2, 47. S100A9 KO mice displayed decreased recruitment of myofibroblasts, collagen deposits and pro‐fibrotic mediators, suggesting that injury was contained in TECs, as the inflammatory compartment was unaffected. Indeed, S100A9KO mice displayed improved renal function and decreased tubular injury, which resulted in decreased activation of critical EMT steps in TECs. Among S100A8/A9 receptors, RAGE and its interacting receptor ICAM‐1 have been shown to mediate renal fibrosis via the loss of epithelial cell integrity and by modulating cellular apoptosis 17. Other members of the S100 family are known to trigger cell death in cancer cells by binding to RAGE 48. Expression of RAGE and its interacting receptor ICAM‐1 was dampened in the absence of S100A9 after UUO. However, more experiments are needed to ascertain whether S100A8/A9‐mediated tubular injury and renal fibrosis may be dependent upon the RAGE‐ICAM‐1 interaction. Our data argue in favour of a possible involvement.
Finally, we explored the mechanism by which S100A8/A9 may contribute to tubular injury and fibrosis. We found that tubular epithelial cell lines stimulated with low concentrations of rS100A8/A9 displayed down‐regulation of tight junction protein ZO‐1 and adhesion molecule E‐cadherin, together with cell‐cycle arrest. Extracellular S100A8/A9 can affect cell growth and have cytotoxic/apoptotic effects on different cell types in a dose‐dependent manner 30, 31, 49, 50. Our results are in unison with these studies, as a high concentration of rS100A8/A9 induced a caspase‐independent cell death in TECs, most probably necrosis. However when rS100A8/A9 is combined with a pro‐fibrotic trigger, tubular apoptosis is pronounced. Increasing evidence describes a relationship between cell‐cycle arrest and renal fibrosis 51. The reduction of fibrosis observed in S100A9 KO mice may be explained partially by the decreased tubular apoptosis and destruction.
We believe that treatment with recombinant protein induces dissolution of the cell–cell junction, which is essential for maintaining tubular structure and may lead to cell death by necrosis. Consistent with our results, S100A8/A9 was shown to induce loss of endothelial cell contact which triggered subsequent cell death, not exclusively via the apoptotic pathway 30. However, during progression of fibrosis, S100A8/A9 affects mainly tubular apoptosis, as confirmed in vivo and in vitro.
In conclusion, our study demonstrates that S100A8/A9 mediates tubular apoptosis and renal fibrosis presumably through the loss of TECs contacts and activation of EMT transition steps. Targeting the TLR‐4 and RAGE shared ligand, S100A8/A9, could be a therapeutic strategy to halt renal fibrosis and parenchymal damage in patients with CKD.
Disclosure
The authors declare no potential conflicts of interest to disclose.
Supporting information
Additional Supporting information may be found in the online version of this article at the publisher’s web‐site:
Table S1. Reverse transcriptase–polymerase chain reaction (RT–PCR) primer sequences
Table S2. Antibodies list Western blot
Fig. S1. Cellular expression of S100A8/A9 after 14 days of unilateral ureteral obstruction (UUO). Representative pictures of immunofluorescence staining on kidney tissue from WT mice, 14 days post‐UUO, with S100A8 or S100A9 (red), DolichosBiflorus Agglutinin (DBA: collecting duct marker) and lotus tetragonolobus lectin (LTL: proximal tubule marker), both in green. Nuclei were stained with Hoechst (blue). S100A8 or S100A9, DBA and Hoechst‐positive staining are merged (magnification ×40).
Fig. S2. Effect of S100A8/A9 on a polarized system of tubular epithelial cells. Representative pictures of ZO‐1 and E‐cadherin immunofluorescence staining of Madin–Darby canine kidney (MDCK) cell line, cultured on collagen‐coated coverslip in HK2 medium and stimulated with increasing concentration of rS100A8/A9 for 24 h. Both primary antibodies were detected with an Alexa‐Fluor 488 conjugated secondary antibody. Hoechst was used for nuclear staining. Magnification ×40.
Fig. S3. Effect of S100A8/A9 on epithelial cell death after ligand activation. Caspase‐3 enzyme activity measurement by DEVD‐AMC) cleavage. IM‐TECs were stimulated for 24 h with rS100A8/A9 in the presence or not of Toll‐like receptor (TLR)‐4 inhibitor (CLI095) and receptor for advanced glycation end‐products (RAGE) antagonist (FPSZM‐1). Staurosporine (stauro) and a PAN‐caspase inhibitor Q‐VD‐OPh hydrate (QVD) were used as experimental controls. Statistical differences were analysed by two‐tailed Student’s t‐test Data are expressed as mean ± standard error of the mean (s.e.m). ***P < 0·0005 versus unstimulated control (white bar).
Acknowledgements
The authors would like to acknowledge Angelique Scantlebery for proof‐reading the paper. This work was supported further by the Dutch Kidney Foundation and the Netherlands Organization for Health Research and Development (ZonMw) to M. D. (Meer Kennis met Minder Dieren; no. 114024040) and J. C. L. (Vidi #91712386), (ASPASIA no. 015.008.044).
References
- 1. Rockey DC, Bell PD, Hill JA. Fibrosis: a common pathway to organ injury and failure. N Engl J Med 2015;372:1138–49. [DOI] [PubMed] [Google Scholar]
- 2. Lovisa S, LeBleu VS, Tampe B et al Epithelial‐to‐mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med 2015;21:998–1009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Lovisa S, Zeisberg M, Kalluri R. Partial epithelial‐to‐mesenchymal transition and other new mechanisms of kidney fibrosis. Trends Endocrinol Metab 2016;27:681–95. [DOI] [PubMed] [Google Scholar]
- 4. Vogl T, Ludwig S, Goebeler M et al MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood 2004;104:4260–8. [DOI] [PubMed] [Google Scholar]
- 5. Lackmann M, Rajasekariah P, Iismaa SE et al Identification of a chemotactic domain of the pro‐inflammatory S100 protein CP‐10. J Immunol. 1993;150:2981–91. [PubMed] [Google Scholar]
- 6. Simard J‐C, Cesaro A, Chapeton‐Montes J et al S100A8 and S100A9 induce cytokine expression and regulate the NLRP3 inflammasome via ROS‐dependent activation of NF‐κB1. PLOS ONE 2013;8:e72138. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003;60:540–51. [DOI] [PubMed] [Google Scholar]
- 8. Donato R, Cannon BR, Sorci G et al Functions of S100 proteins. Curr Mol Med 2013;13:24–57. [PMC free article] [PubMed] [Google Scholar]
- 9. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991–1045. [DOI] [PubMed] [Google Scholar]
- 10. Leemans JC, Kors L, Anders H‐J, Florquin S. Pattern recognition receptors and the inflammasome in kidney disease. Nat Rev Nephrol 2014;10:398–414. [DOI] [PubMed] [Google Scholar]
- 11. Anders H‐J, Schaefer L. Beyond tissue injury‐damage‐associated molecular patterns, toll‐like receptors, and inflammasomes also drive regeneration and fibrosis. J Am Soc Nephrol 2014;25:1387–400. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Johnson GB, Brunn GJ, Platt JL. Activation of mammalian toll‐like receptors by endogenous agonists. Crit Rev Immunol. 2003;23:15–44. [DOI] [PubMed] [Google Scholar]
- 13. Vogl T, Tenbrock K, Ludwig S et al Mrp8 and Mrp14 are endogenous activators of toll‐like receptor 4, promoting lethal, endotoxin‐induced shock. Nat Med 2007;13:1042–9. [DOI] [PubMed] [Google Scholar]
- 14. Ehlermann P, Eggers K, Bierhaus A et al Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol 2006;5:6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Narumi K, Miyakawa R, Ueda R et al Proinflammatory proteins S100A8/S100A9 activate NK cells via interaction with RAGE. J Immunol 2015;194:5539–48. [DOI] [PubMed] [Google Scholar]
- 16. Yiu WH, Lin M, Tang SCW. Toll‐like receptor activation: from renal inflammation to fibrosis. Kidney Int 2014;4:20–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Gasparitsch M, Arndt A‐K, Pawlitschek F et al RAGE‐mediated interstitial fibrosis in neonatal obstructive nephropathy is independent of NF‐κB activation. Kidney Int 2013;84:911–9. [DOI] [PubMed] [Google Scholar]
- 18. Pulskens WP, Rampanelli E, Teske GJ et al TLR4 promotes fibrosis but attenuates tubular damage in progressive renal injury. J Am Soc Nephrol 2010;21:1299–308. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Tammaro A, Stroo I, Rampanelli E et al Role of TREM1‐DAP12 in renal inflammation during obstructive nephropathy. PLOS ONE 2013;8:e82498. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Passey RJ, Williams E, Lichanska AM et al A null mutation in the inflammation‐associated S100 protein S100A8 causes early resorption of the mouse embryo. J Immunol 1999;163:2209–16. [PubMed] [Google Scholar]
- 21. Dessing MC, Tammaro A, Pulskens WP et al The calcium‐binding protein complex S100A8/A9 has a crucial role in controlling macrophage‐mediated renal repair following ischemia/reperfusion. Kidney Int 2015;87:85–94. [DOI] [PubMed] [Google Scholar]
- 22. Stokman G, Kers J, Yapici Ü et al Predominant tubular interleukin‐18 expression in polyomavirus‐associated nephropathy. Transplantation 2016;100:e88–95. [DOI] [PubMed] [Google Scholar]
- 23. Pulskens WP, Teske GJ, Butter LM et al Toll‐like receptor‐4 coordinates the innate immune response of the kidney to renal ischemia/reperfusion injury. PLOS ONE 2008;3:e3596. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Stokman G, Qin Y, Genieser H‐G et al Epac‐rap signaling reduces cellular stress and ischemia‐induced kidney failure. J Am Soc Nephrol 2011;22:859–72. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Bascands J‐L, Schanstra JP. Obstructive nephropathy: insights from genetically engineered animals. Kidney Int 2005;68:925–37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Meng X‐M, Nikolic‐Paterson DJ, Lan HY. Inflammatory processes in renal fibrosis. Nat Rev Nephrol 2014;10:493–503. [DOI] [PubMed] [Google Scholar]
- 27. Fujiu K, Manabe I, Nagai R. Renal collecting duct epithelial cells regulate inflammation in tubulointerstitial damage in mice. J Clin Invest 2011;121:3425–41. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial‐mesenchymal transition. Nat Rev Mol Cell Biol 2014;15:178–96. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Jin Y, Liu R, Xie J, Xiong H, He JC, Chen N. Interleukin‐10 deficiency aggravates kidney inflammation and fibrosis in the unilateral ureteral obstruction mouse model. Lab Invest 2013;93:801–11. [DOI] [PubMed] [Google Scholar]
- 30. Viemann D, Barczyk K, Vogl T et al MRP8/MRP14 impairs endothelial integrity and induces a caspase‐dependent and ‐independent cell death program. Blood 2007;109:2453. [DOI] [PubMed] [Google Scholar]
- 31. Viemann D, Strey A, Janning A et al Myeloid‐related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood 2005;105:2955–62. [DOI] [PubMed] [Google Scholar]
- 32. Pruenster M, Vogl T, Roth J, Sperandio M. S100A8/A9: From basic science to clinical application. Pharmacol Ther 2016;167:120–31. [DOI] [PubMed] [Google Scholar]
- 33. Perera C, McNeil HP, Geczy CL. S100 Calgranulins in inflammatory arthritis. Immunol Cell Biol 2010;88:41–9. [DOI] [PubMed] [Google Scholar]
- 34. Eikmans M, Roos‐van Groningen MC, Sijpkens YW et al Expression of surfactant protein‐C, S100A8, S100A9, and B cell markers in renal allografts: investigation of the prognostic value. J Am Soc Nephrol 2005;16:3771–86. [DOI] [PubMed] [Google Scholar]
- 35. Rekers NV, Bajema IM, Mallat MJK et al Beneficial immune effects of myeloid‐related proteins in kidney transplant rejection. Am J Transplant 2016;16:1441–55. [DOI] [PubMed] [Google Scholar]
- 36. Ikhtaire S, Shajib MS, Reinisch W, Khan WI. Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease. J Gastroenterol 2016;51:434–46. [DOI] [PubMed] [Google Scholar]
- 37. Kuipers MT, Vogl T, Aslami H et al High levels of S100A8/A9 proteins aggravate ventilator‐induced lung injury via TLR4 signaling. PLOS ONE 2013;8:e68694. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Xu X, Wu W, Tu W et al Increased expression of S100A8 and S100A9 in patients with diffuse cutaneous systemic sclerosis. A correlation with organ involvement and immunological abnormalities. Clin Rheumatol. 2013;32:1501–10. [DOI] [PubMed] [Google Scholar]
- 39. Xu X, Wu W‐y, Tu W‐z et al S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol 2013;32:1501–229. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Henke MO, Renner A, Rubin BK, Gyves JI, Lorenz E, Koo JS. UP‐regulation of S100A8 and S100A9 protein in bronchial epithelial cells by lipopolysaccharide. Exp Lung Res 2006;32:331–47. [DOI] [PubMed] [Google Scholar]
- 41. Chen G, Gharib TG, Huang C‐C et al Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002;1:304–13. [DOI] [PubMed] [Google Scholar]
- 42. Höchst B, Mikulec J, Baccega T et al Differential induction of Ly6G and Ly6C positive myeloid derived suppressor cells in chronic kidney and liver inflammation and fibrosis. PLOS ONE 2015;10:e0119662. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Nikolic‐Paterson DJ, Wang S, Lan HY. Macrophages promote renal fibrosis through direct and indirect mechanisms. Kidney Int Suppl 2014;4:34–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Yan L, Mathew L, Chellan B et al S100/Calgranulin‐mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products‐dependent manner. Arterioscler Thromb Vasc Biol 2014;34:1399–411. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Wu Y, Li Y, Zhang C et al S100a8/a9 released by CD11b+Gr1+ neutrophils activates cardiac fibroblasts to initiate angiotensin II‐Induced cardiac inflammation and injury. Hypertension 2014;63:1241–50. [DOI] [PubMed] [Google Scholar]
- 46. Leemans JC, Stokman G, Claessen N et al Renal‐associated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest 2005;115:2894–903. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Grande MT, Sánchez‐Laorden B, López‐Blau C et al Snail1‐induced partial epithelial‐to‐mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat Med 2015;21:989–97. [DOI] [PubMed] [Google Scholar]
- 48. Jin Q, Chen H, Luo A, Ding F, Liu Z. S100A14 stimulates cell proliferation and induces cell apoptosis at different concentrations via receptor for advanced glycation end products (RAGE). PLoS One 2011;6:e19375. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Yui S, Mikami M, Tsurumaki K, Yamazaki M. Growth‐inhibitory and apoptosis‐inducing activities of calprotectin derived from inflammatory exudate cells on normal fibroblasts: regulation by metal ions. J Leukoc Biol 1997;61:50–7. [PubMed] [Google Scholar]
- 50. Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis‐inducing activity. Biol Pharm Bull 2003;26:753–60. [DOI] [PubMed] [Google Scholar]
- 51. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010;16:535–43. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Additional Supporting information may be found in the online version of this article at the publisher’s web‐site:
Table S1. Reverse transcriptase–polymerase chain reaction (RT–PCR) primer sequences
Table S2. Antibodies list Western blot
Fig. S1. Cellular expression of S100A8/A9 after 14 days of unilateral ureteral obstruction (UUO). Representative pictures of immunofluorescence staining on kidney tissue from WT mice, 14 days post‐UUO, with S100A8 or S100A9 (red), DolichosBiflorus Agglutinin (DBA: collecting duct marker) and lotus tetragonolobus lectin (LTL: proximal tubule marker), both in green. Nuclei were stained with Hoechst (blue). S100A8 or S100A9, DBA and Hoechst‐positive staining are merged (magnification ×40).
Fig. S2. Effect of S100A8/A9 on a polarized system of tubular epithelial cells. Representative pictures of ZO‐1 and E‐cadherin immunofluorescence staining of Madin–Darby canine kidney (MDCK) cell line, cultured on collagen‐coated coverslip in HK2 medium and stimulated with increasing concentration of rS100A8/A9 for 24 h. Both primary antibodies were detected with an Alexa‐Fluor 488 conjugated secondary antibody. Hoechst was used for nuclear staining. Magnification ×40.
Fig. S3. Effect of S100A8/A9 on epithelial cell death after ligand activation. Caspase‐3 enzyme activity measurement by DEVD‐AMC) cleavage. IM‐TECs were stimulated for 24 h with rS100A8/A9 in the presence or not of Toll‐like receptor (TLR)‐4 inhibitor (CLI095) and receptor for advanced glycation end‐products (RAGE) antagonist (FPSZM‐1). Staurosporine (stauro) and a PAN‐caspase inhibitor Q‐VD‐OPh hydrate (QVD) were used as experimental controls. Statistical differences were analysed by two‐tailed Student’s t‐test Data are expressed as mean ± standard error of the mean (s.e.m). ***P < 0·0005 versus unstimulated control (white bar).
